Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study
MIHAYLOVA B. et al, (2024), The Lancet Regional Health - Europe
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial.
Zhou J. et al, (2023), Pharmacoeconomics
Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
Wu R. et al, (2023), British Journal of General Practice
A systematic review of the factors associated with suicide attempts among sexual-minority youth
Wang XX. et al, (2023), The European Journal of Psychiatry, 37, 72 - 83
Cost-effectiveness of endovascular thrombectomy with alteplase versus endovascular thrombectomy alone for acute ischemic stroke secondary to large vessel occlusion.
Ye Z. et al, (2023), CMAJ Open, 11, E443 - E450
Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis.
Wang K. et al, (2023), Front Aging Neurosci, 15
Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK
Zhou J. et al, (2022), PharmacoEconomics
CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA
Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16
EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS
Zhou J. et al, (2022), VALUE IN HEALTH, 25, S12 - S12
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
Guo M. et al, (2021), International Journal of Clinical Pharmacy, 43, 1508 - 1515
A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts
Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149
Incorporating future unrelated medical costs in cost-effectiveness analysis in China.
Jiang S. et al, (2021), BMJ Glob Health, 6
Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries
Wang Y. et al, (2021), Applied Health Economics and Health Policy, 19, 281 - 304
Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
Clay E. et al, (2019), Journal of Market Access & Health Policy, 7, 1667195 - 1667195
Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
Zhou J. et al, (2019), Journal of Market Access & Health Policy, 7, 1648973 - 1648973